: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

Celgene: Buy On A Pullback

Wed, 04 Nov 2009 17:04:19 GMT

“So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It’s approved by the FDA to treat multiple myeloma. That’s a cancer of the plasma cells and bone marrow. These cancers are horrible…[More...]

What Investors Should Look for In Today’s Fed Statement

Wed, 04 Nov 2009 13:04:24 GMT

In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).[More...]

Are Discount Brokers Shares Worth Owning?

Wed, 04 Nov 2009 01:28:03 GMT

The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&P gain 15%.[More...]

Technology Rises And Buying Facebook

Tue, 03 Nov 2009 16:54:11 GMT

Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%. Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.[More...]

Buffett Gets His Cheque Book Out

Tue, 03 Nov 2009 16:17:34 GMT

Given the slew of positive economic data Monday you might have been forgiven for expecting a decent rebound in risk assets. There was a rebound of sorts in early New York trading, with the Dow up close to 150 points at one stage.[More...]

Finding the Road to Riches

Mon, 19 Oct 2009 15:46:00 GMT

Have you run across statements like this?
Of course, X is always a large number like $500,000 or $1 million.
Back when he made that investment, he paid a very large commission, as brokers charged a lot at the time and they also charged more for trades involving fewer shares than a "round lot" of 100.

: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Bulls Back On Track?

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Your Kind of Day?

The Dollar-Proof Portfolio

Celgene: Buy On A Pullback

What Investors Should Look for In Today’s Fed Statement

Are Discount Brokers Shares Worth Owning?

Technology Rises And Buying Facebook

Buffett Gets His Cheque Book Out

Finding the Road to Riches

Lennar, Wal-Mart, Jack in the Box big movers

Celgene Q2 Net Income Rises

Stocks Finish Mixed

Stocks: Finding Long-Term Winners

Takeda Incurs 1st Profit Fall in 4 Years in FY 2008

Taking Stock: Nobody Wins for 2008

Investors Can Consider No-Risk, Low-Risk Options

Health Care Poised to Weather Recession

Health care, defense poised to weather recession

MethylGene Reports Third Quarter 2009 Financial Results

Celgene Reports Record Third Quarter 2009 Operating and Financial Results

Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments

GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2009

Clinical Data Evaluating Amrubicin® as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer

VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network (NCCN) in Its Clinical Practice Guidelines

Celgene Corporation to Present at Two Upcoming Investor Conferences

MethylGene Reports Second Quarter 2009 Financial Results

Celgene Reports Record Second Quarter 2009 Operating and Financial Results

Celgene Corporation to Announce Second Quarter Results on July 23, 2009

Form 4 CELGENE CORP /DE/ For: Oct 27 Filed by: Burton Graham (10K)

Form 4 GRYSKA DAVID W For: Oct 13 (10K)

Form 4 Burton Graham For: Oct 13 (10K)

Form 4 BARER SOL J For: Oct 13 (10K)

Form 4 HUGIN ROBERT J For: Oct 13 (10K)

Form 4 Van Hoek Andre For: Oct 13 (10K)

Form 4 HUGIN ROBERT J For: Oct 05 (10K)

Form 4 Van Hoek Andre For: Oct 01 (10K)

Form 4 BARER SOL J For: Sep 14 (10K)

Form 4 CELGENE CORP /DE/ For: Sep 04 Filed by: KAPLAN GILLA (10K)